1. Home
  2. OMER vs MNTK Comparison

OMER vs MNTK Comparison

Compare OMER & MNTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OMER
  • MNTK
  • Stock Information
  • Founded
  • OMER 1994
  • MNTK 1980
  • Country
  • OMER United States
  • MNTK United States
  • Employees
  • OMER N/A
  • MNTK N/A
  • Industry
  • OMER Biotechnology: Pharmaceutical Preparations
  • MNTK Natural Gas Distribution
  • Sector
  • OMER Health Care
  • MNTK Utilities
  • Exchange
  • OMER Nasdaq
  • MNTK Nasdaq
  • Market Cap
  • OMER 304.9M
  • MNTK 306.2M
  • IPO Year
  • OMER 2009
  • MNTK 2021
  • Fundamental
  • Price
  • OMER $4.19
  • MNTK $2.19
  • Analyst Decision
  • OMER Strong Buy
  • MNTK Hold
  • Analyst Count
  • OMER 5
  • MNTK 3
  • Target Price
  • OMER $18.00
  • MNTK $3.33
  • AVG Volume (30 Days)
  • OMER 1.2M
  • MNTK 225.4K
  • Earning Date
  • OMER 08-14-2025
  • MNTK 08-06-2025
  • Dividend Yield
  • OMER N/A
  • MNTK N/A
  • EPS Growth
  • OMER N/A
  • MNTK N/A
  • EPS
  • OMER N/A
  • MNTK 0.02
  • Revenue
  • OMER N/A
  • MNTK $181,341,000.00
  • Revenue This Year
  • OMER N/A
  • MNTK $3.74
  • Revenue Next Year
  • OMER $9,040.39
  • MNTK $3.88
  • P/E Ratio
  • OMER N/A
  • MNTK $119.50
  • Revenue Growth
  • OMER N/A
  • MNTK N/A
  • 52 Week Low
  • OMER $2.95
  • MNTK $1.68
  • 52 Week High
  • OMER $13.60
  • MNTK $6.04
  • Technical
  • Relative Strength Index (RSI)
  • OMER 52.49
  • MNTK 54.50
  • Support Level
  • OMER $4.06
  • MNTK $1.98
  • Resistance Level
  • OMER $4.58
  • MNTK $2.26
  • Average True Range (ATR)
  • OMER 0.26
  • MNTK 0.10
  • MACD
  • OMER -0.02
  • MNTK 0.03
  • Stochastic Oscillator
  • OMER 42.75
  • MNTK 85.71

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

About MNTK Montauk Renewables Inc.

Montauk Renewables Inc is a renewable energy company. It specializes in the recovery and processing of biogas from landfills and other non-fossil fuel sources for beneficial use as a replacement for fossil fuels. The firm develops, owns, and operates RNG projects that supply renewable fuel into the transportation and electrical power sectors. Montauk operates in two segments namely Renewable Natural Gas and Renewable Electricity Generation. It generates a majority of its revenue from the Renewable Natural Gas segment.

Share on Social Networks: